GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ATAI Life Sciences NV (FRA:9VC) » Definitions » Enterprise Value

ATAI Life Sciences NV (FRA:9VC) Enterprise Value : €231.66 Mil (As of May. 03, 2025)


View and export this data going back to 2021. Start your Free Trial

What is ATAI Life Sciences NV Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, ATAI Life Sciences NV's Enterprise Value is €231.66 Mil. ATAI Life Sciences NV's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was €-135.02 Mil. Therefore, ATAI Life Sciences NV's EV-to-EBIT ratio for today is -1.72.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, ATAI Life Sciences NV's Enterprise Value is €231.66 Mil. ATAI Life Sciences NV's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was €-134.57 Mil. Therefore, ATAI Life Sciences NV's EV-to-EBITDA ratio for today is -1.72.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, ATAI Life Sciences NV's Enterprise Value is €231.66 Mil. ATAI Life Sciences NV's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was €0.29 Mil. Therefore, ATAI Life Sciences NV's EV-to-Revenue ratio for today is 812.83.

EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, ATAI Life Sciences NV's Enterprise Value is €231.66 Mil. ATAI Life Sciences NV's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was €-76.56 Mil. Therefore, ATAI Life Sciences NV's EV-to-FCF ratio for today is -3.03.


ATAI Life Sciences NV Enterprise Value Historical Data

The historical data trend for ATAI Life Sciences NV's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ATAI Life Sciences NV Enterprise Value Chart

ATAI Life Sciences NV Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Enterprise Value
Get a 7-Day Free Trial - 742.10 154.85 80.29 166.54

ATAI Life Sciences NV Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 80.29 194.33 152.18 119.27 166.54

Competitive Comparison of ATAI Life Sciences NV's Enterprise Value

For the Biotechnology subindustry, ATAI Life Sciences NV's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ATAI Life Sciences NV's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ATAI Life Sciences NV's Enterprise Value distribution charts can be found below:

* The bar in red indicates where ATAI Life Sciences NV's Enterprise Value falls into.


;
;

ATAI Life Sciences NV Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

ATAI Life Sciences NV's Enterprise Value for the fiscal year that ended in Dec. 2024 is calculated as

ATAI Life Sciences NV's Enterprise Value for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ATAI Life Sciences NV  (FRA:9VC) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

ATAI Life Sciences NV's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=231.657/-135.016
=-1.72

ATAI Life Sciences NV's current Enterprise Value is €231.66 Mil.
ATAI Life Sciences NV's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-135.02 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

ATAI Life Sciences NV's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=231.657/-134.574
=-1.72

ATAI Life Sciences NV's current Enterprise Value is €231.66 Mil.
ATAI Life Sciences NV's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-134.57 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

ATAI Life Sciences NV's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=231.657/0.285
=812.83

ATAI Life Sciences NV's current Enterprise Value is €231.66 Mil.
ATAI Life Sciences NV's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.29 Mil.

4. EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow.

ATAI Life Sciences NV's EV-to-FCF for today is:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=231.657/-76.562
=-3.03

ATAI Life Sciences NV's current Enterprise Value is €231.66 Mil.
ATAI Life Sciences NV's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-76.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ATAI Life Sciences NV Enterprise Value Related Terms

Thank you for viewing the detailed overview of ATAI Life Sciences NV's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


ATAI Life Sciences NV Business Description

Traded in Other Exchanges
Address
Wallstrasse 16, Berlin, BB, DEU, 10179
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.

ATAI Life Sciences NV Headlines

No Headlines